McCune-Albright syndrome.
Feuillan
P P
PP
National Institutes of Health, Bethesda, Maryland.
D000293:Adolescent; D002117:Calcitriol / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010052:Ovariectomy; D011441:Propylthiouracil / Q000627:therapeutic use; D011629:Puberty, Precocious / Q000503:physiopathology / Q000628:therapy; D013148:Spironolactone / Q000627:therapeutic use; D013738:Testolactone / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000150:complications
D013148:Spironolactone; D013738:Testolactone; D011441:Propylthiouracil; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide; D002117:Calcitriol; D007654:Ketoconazole; D015282:Octreotide